Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Immunology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Clinical Trials

A listing of Immune (Idiopathic) Thrombocytopenic Purpura (ITP) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (13) clinical trials

A Study to Assess Safety Tolerability Pharmacokinetics and Pharmacodynamics of Multiple- Dose TNT009 in Participants With Chronic Immune Thrombocytopenia (ITP)

The purpose of this study is to explore the safety, preliminary clinical benefit, and activity of TNT009 in patients with chronic immune thrombocytopenia.

Phase

The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.

Primary immune thrombocytopenia (ITP) is an acquired immune-mediated disorder characterized by isolated thrombocytopenia, defined as a peripheral blood platelet count less than 100 109/l and the absence of any obvious initiating and/ or underlying cause of the thrombocytopenia. (Buchanan, 1989). Novel thrombopoiesis-stimulating agents have been developed increasing platelet production by ...

Phase N/A

H. Pylori Eradication for Moderate ITP

Current treatment guideline of ITP recommends corticosteroid as the first line treatment when patient has active bleeding or less than 3010^9/L of platelet, because of side effect and cost issues. Since the first case report by Italian study, several investigators have reported that secondary immune thrombocytopenia (ITP) can occur in ...

Phase

The PROLONG Trial - Rituximab Maintenance Therapy in ITP

This is a multi-center, international, randomized, two-phase study: First phase (induction phase) is open-label, hypothesis-generating, involving 1:1 randomization into: rituximab (group 1) or rituximab plus dexamethasone (group 2) to determine if the response to rituximab can be improved by the addition of dexamethasone. Second Phase (maintenance phase) is the main ...

Phase

A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disease characterized by the presence of platelet autoantibodies, low platelet counts and an increased risk of bleeding. TPO receptor agonists which stimulate platelet production have been shown to be remarkably effective in ITP. Their use as a short-term means of elevating platelet counts ...

Phase

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

Protocol: TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low doses IL2 across 14 selected pathologies: rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet's disease, Wegener's granulomatosis, Takayasu's disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis, sclerosing cholangitis, Gougerot-sjgren, Systemic Sclerosis and ...

Phase

A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)

This is an adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/L on two counts no sooner than 7 days apart in the 15 days before treatment begins. The active treatment period ...

Phase

Association of Fc RIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

Immune thrombocytopenic purpura (ITP) is a autoimmune disorder in which a decreased number of circulating platelets (thrombocytopenia) manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae). In persons with ITP, platelets are coated with autoantibodies to platelet membrane antigens, ...

Phase

Multicentre Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with chronic, previously treated ITP. Dosage could be adjusted (2.5~.75 mg/day) to maintain platelet counts 50~250109/L

Phase

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

This is an open-label Phase III extension study to evaluate the long-term safety of eltrombopag in pediatric patients with chronic ITP who previously participated in study TRA115450. This study will allow dosing of eltrombopag at an individualized dose for each subject based upon platelet count. The starting dose will be ...

Phase